My watch list
my.bionity.com  
Login  

CSL Limited



CSL Limited
Public
ASX: CSL
Founded1994 (privatised), 1916 (government department)
HeadquartersMelbourne,  Australia Australia
Key peopleBrian A McNamee (CEO)
Industrymedicine
Productsblood plasma, vaccines, antivenom, other laboratory and medical products
Revenue$3,310 million AUD (Y.E. 30 June 2007)
Websitewww.csl.com.au

CSL Limited is an Australian-based manufacturer of medical products. Its products include various blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing.

Additional recommended knowledge

Contents

History

Founded in 1916 the Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture. The operation commenced plasma fractionation in 1952. It was privatised as CSL Ltd in 1994. In 2000 CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG. In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring. The company was the 2nd Australian public comapny to have reached a share price of over $100 per share.

Locations

The company's headquarters remain in Parkville, Victoria, an inner suburb of Melbourne. CSL Behring is headquartered in King of Prussia, Pennsylvania and has manufacturing operations in the Swiss city of Berne, in Marburg in Germany, and Bradley, Illinois.

Ownership

CSL is a public company whose stock is traded on the Australian Stock Exchange under the stock code CSL. The company completed an Initial Public Offering in June 1994 at A$2.30 per share. Today CSL stock is part of the S&P/ASX 50 Index.

Products

CSL Limited's products can be separated by company division. Some of the key products produced by each division, circa 2006, include:

CSL Vaccines

Vaccines

Antivenoms

CSL Pharmaceuticals

CSL Behring

  • Beriate, which is freeze-dried human factor VIII concentrate
  • Berinin, freeze-dried human factor IX concentrate
  • Helixate FS, freeze-dried recombinant coagulation factor VIII. CSL is working on a new Helixate product called "Helixate NexGen".
  • Humate-P, freeze-dried human coagulation factor VIII/von Willebrand factor complex
  • Monoclate, a freeze-dried human coagulation factor VIII that has been purified using monoclonal antibodies
  • Mononine, a freeze-dried human coagulation factor IX that has been purified using monoclonal antibodies
  • Stimate, a synthetic desmopressin acetate nasal spray

CSL Bioplasma

  • Albumex (serum albumin)
  • Biostate (Factor VIII)
  • Carimune, which is immunoglobulin for intravenous administration (IGIV)
  • CMV Immunoglobulin-VF (cytomegalovirus immunoglobulin)
  • Helixate, which is recombinant Antihemophilic Factor, a blood-clotting factor for the treatment of haemophilia
  • Hepatitis B immunoglobulin
  • human immunoglobulin – Intragam P, Normal, Rh(D) Immunoglobulin-VF, Sandoglobulin,
  • MonoFIX-VF (Factor IX)
  • Prothrombinex-HT (prothrombin complex)
  • Tetanus Immunoglobulin-VF
  • Thrombotrol-VF (antithrombin III)
  • Vivaglobin, sub-cutaneous human immune globulin indicated for the treatment of primary immunodeficiency. This product gained FDA approval in January 2006.
  • Von Willebrand factor
  • WinRho SDF (Rh(D) immunoglobulin G)
  • Zoster Immunoglobulin-VF (varicella zoster immunoglobulin)

See also

  • Australian Red Cross Blood Service
  • Australian Venom Research Unit
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "CSL_Limited". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE